Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Alimentary Pharmacology & Therapeutics
|
March 13, 2010
Infliximab for refractory ulcerative proctitis
G Bouguen, X Roblin, A Bourreille, et al.
Italian Journal of Gastroenterology and Hepatology
|
June 6, 1998
Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group
I Wiklund, K D Bardhan, S Müller-Lissner, et al.
BMJ (Clinical Research Ed.)
|
February 19, 1999
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group
K D Bardhan, S Müller-Lissner, M A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
July 29, 2008
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression
L Peyrin-Biroulet, J-F Cadranel, J-B Nousbaum, et al.
The European Journal of Surgery. Supplement. : = Acta Chirurgica. Supplement
|
February 23, 1999
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)
I K Wiklund, O Junghard, E Grace, et al.
Journal of Hepatology
|
March 1, 1996
Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma
J P Bronowicki, K Boudjema, L Chone, et al.
Pharmacoeconomics
|
February 8, 2000
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease
N O Stålhammar, J Carlsson, R Peacock, et al.
Alimentary Pharmacology & Therapeutics
|
March 5, 2003
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
K Lauritsen, J Devière, M-A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
February 4, 2003
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
K Lauritsen, J Devière, M-A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
August 28, 2009
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M Allez, S Vermeire, N Mozziconacci, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Alimentary Pharmacology & Therapeutics
|
March 13, 2010
Infliximab for refractory ulcerative proctitis
G Bouguen, X Roblin, A Bourreille, et al.
Italian Journal of Gastroenterology and Hepatology
|
June 6, 1998
Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group
I Wiklund, K D Bardhan, S Müller-Lissner, et al.
BMJ (Clinical Research Ed.)
|
February 19, 1999
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group
K D Bardhan, S Müller-Lissner, M A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
July 29, 2008
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression
L Peyrin-Biroulet, J-F Cadranel, J-B Nousbaum, et al.
The European Journal of Surgery. Supplement. : = Acta Chirurgica. Supplement
|
February 23, 1999
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)
I K Wiklund, O Junghard, E Grace, et al.
Journal of Hepatology
|
March 1, 1996
Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma
J P Bronowicki, K Boudjema, L Chone, et al.
Pharmacoeconomics
|
February 8, 2000
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease
N O Stålhammar, J Carlsson, R Peacock, et al.
Alimentary Pharmacology & Therapeutics
|
March 5, 2003
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
K Lauritsen, J Devière, M-A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
February 4, 2003
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
K Lauritsen, J Devière, M-A Bigard, et al.
Alimentary Pharmacology & Therapeutics
|
August 28, 2009
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M Allez, S Vermeire, N Mozziconacci, et al.
Page
of 8